SSTR2 expression in EBV-positive and EBV-negative lymphomas.

IF 0.6 4区医学 Q4 HEMATOLOGY

Journal of Hematopathology Pub Date : 2026-04-10 DOI:10.1007/s12308-026-00693-7

Nivaz Brar, Juan Carlos Barrios-Menéndez, Gregory W Charville, Edward L Briercheck, Yasodha Natkunam, Fabiola Valvert, Oscar Silva

{"title":"SSTR2 expression in EBV-positive and EBV-negative lymphomas.","authors":"Nivaz Brar, Juan Carlos Barrios-Menéndez, Gregory W Charville, Edward L Briercheck, Yasodha Natkunam, Fabiola Valvert, Oscar Silva","doi":"10.1007/s12308-026-00693-7","DOIUrl":null,"url":null,"abstract":"Background: Somatostatin receptor 2 (SSTR2) protein expression is aberrantly upregulated in various tumors and can be visualized using scintigraphy or radiological techniques and therapeutically targeted using octreotide-based molecules.Purpose: In this study, we assessed SSTR2 expression in the largest cohort of hematopoietic proliferations examined to date and interrogated the relationship between EBV and SSTR2 in EBV-associated lymphomas as a possible mechanism for SSTR2 upregulation.Methods: We retrospectively identified 407 cases of lymphoma from Guatemala, a country with a high prevalence of EBV-associated lymphomas. SSTR2 protein expression was assessed by immunohistochemistry, while EBV was assessed by in situ hybridization for EBV-associated small RNAs.Results: We found SSTR2 expression in 43% (20/47) of EBV-positive classic Hodgkin lymphomas (cHL) and 0% (0/12) of EBV-negative cHL cases. All but one of the other EBV-associated lymphomas (n = 53) were negative for SSTR2. Within the EBV-negative non-Hodgkin lymphomas assessed, 33% (1/3) of diffuse large B-cell lymphoma (DLBCL)/high-grade B-cell lymphoma (HGBL) with MYC and BCL2 rearrangement, 17% (25/149) of DLBCL not otherwise specified, and 17% (5/29) of follicular lymphomas showed SSTR2 expression. All other lymphomas showed no significant SSTR2 expression.Conclusions: Our study demonstrates that EBV infection is required, but not sufficient, to upregulate SSTR2 in classic Hodgkin lymphoma, but not in other EBV-associated lymphomas. We also provide data to suggest that SSTR2 is associated with \"higher-grade\" germinal center-derived B-cell lymphomas in EBV-negative non-Hodgkin lymphomas.","PeriodicalId":51320,"journal":{"name":"Journal of Hematopathology","volume":"19 1","pages":""},"PeriodicalIF":0.6000,"publicationDate":"2026-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hematopathology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12308-026-00693-7","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Somatostatin receptor 2 (SSTR2) protein expression is aberrantly upregulated in various tumors and can be visualized using scintigraphy or radiological techniques and therapeutically targeted using octreotide-based molecules.

Purpose: In this study, we assessed SSTR2 expression in the largest cohort of hematopoietic proliferations examined to date and interrogated the relationship between EBV and SSTR2 in EBV-associated lymphomas as a possible mechanism for SSTR2 upregulation.

Methods: We retrospectively identified 407 cases of lymphoma from Guatemala, a country with a high prevalence of EBV-associated lymphomas. SSTR2 protein expression was assessed by immunohistochemistry, while EBV was assessed by in situ hybridization for EBV-associated small RNAs.

Results: We found SSTR2 expression in 43% (20/47) of EBV-positive classic Hodgkin lymphomas (cHL) and 0% (0/12) of EBV-negative cHL cases. All but one of the other EBV-associated lymphomas (n = 53) were negative for SSTR2. Within the EBV-negative non-Hodgkin lymphomas assessed, 33% (1/3) of diffuse large B-cell lymphoma (DLBCL)/high-grade B-cell lymphoma (HGBL) with MYC and BCL2 rearrangement, 17% (25/149) of DLBCL not otherwise specified, and 17% (5/29) of follicular lymphomas showed SSTR2 expression. All other lymphomas showed no significant SSTR2 expression.

Conclusions: Our study demonstrates that EBV infection is required, but not sufficient, to upregulate SSTR2 in classic Hodgkin lymphoma, but not in other EBV-associated lymphomas. We also provide data to suggest that SSTR2 is associated with "higher-grade" germinal center-derived B-cell lymphomas in EBV-negative non-Hodgkin lymphomas.

查看原文本刊更多论文

SSTR2在ebv阳性和ebv阴性淋巴瘤中的表达。

背景：生长抑素受体2 （SSTR2）蛋白表达在多种肿瘤中异常上调，可以通过显像或放射技术观察到，也可以使用基于奥曲肽的分子进行靶向治疗。目的：在这项研究中，我们评估了迄今为止最大的造血增生队列中SSTR2的表达，并询问EBV相关淋巴瘤中EBV和SSTR2之间的关系，作为SSTR2上调的可能机制。方法：我们回顾性分析了危地马拉的407例淋巴瘤病例，这是一个eb病毒相关淋巴瘤高发的国家。免疫组织化学检测SSTR2蛋白表达，EBV相关小rna原位杂交检测EBV。结果：在43% (20/47)ebv阳性的经典霍奇金淋巴瘤（cHL）和0% (0/12)ebv阴性的cHL中发现SSTR2表达。53例ebv相关淋巴瘤（n = 53）除1例外均为SSTR2阴性。在被评估的ebv阴性非霍奇金淋巴瘤中，33%（1/3）的弥漫大b细胞淋巴瘤(DLBCL)/高级别b细胞淋巴瘤（HGBL）伴有MYC和BCL2重排，17%（25/149）的DLBCL未另有说明，17%（5/29）的滤泡性淋巴瘤显示SSTR2表达。其他淋巴瘤均无明显SSTR2表达。结论：我们的研究表明，EBV感染是上调经典霍奇金淋巴瘤中SSTR2的必要条件，但不是充分条件，而在其他EBV相关淋巴瘤中则不是。我们还提供数据表明，在ebv阴性的非霍奇金淋巴瘤中，SSTR2与“高级别”生发中心源性b细胞淋巴瘤有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Hematopathology HEMATOLOGYPATHOLOGY-PATHOLOGY

CiteScore

0.80

自引率

0.00%

发文量

期刊介绍： The Journal of Hematopathology aims at providing pathologists with a special interest in hematopathology with all the information needed to perform modern pathology in evaluating lymphoid tissues and bone marrow. To this end the journal publishes reviews, editorials, comments, original papers, guidelines and protocols, papers on ancillary techniques, and occasional case reports in the fields of the pathology, molecular biology, and clinical features of diseases of the hematopoietic system. The journal is the unique reference point for all pathologists with an interest in hematopathology. Molecular biologists involved in the expanding field of molecular diagnostics and research on lymphomas and leukemia benefit from the journal, too. Furthermore, the journal is of major interest for hematologists dealing with patients suffering from lymphomas, leukemias, and other diseases. The journal is unique in its true international character. Especially in the field of hematopathology it is clear that there are huge geographical variations in incidence of diseases. This is not only locally relevant, but due to globalization, relevant for all those involved in the management of patients.